Hepion Pharmaceuticals, Inc.(HEPA)Earnings, Financials & Key Ratios

HEPA•NASDAQ

$0.06

Price updated Jul 2, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryMetabolic and Obesity Therapies

AboutHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Show more

Revenue$0
EBITDA-$8M+57.3%
Net Income-$8M+37.3%
EPS (Diluted)-0.88+99.2%
ROE-2058.63%-322.7%

HEPA Price & Volume

Hepion Pharmaceuticals, Inc. (HEPA) stock price & volume — 10-year historical chart

Loading chart...

Severe Liquidity Constraints Threaten Clinical Pipeline Viability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity insolvency risk

Key Thesis Takeaways

Hepion Pharmaceuticals faces an existential threat as its clinical development activities have effectively stalled, evidenced by R&D expenditures dropping from $7.1M in 2024Q2 to negligible levels by 2026Q1.
The company's long-term value destruction is highlighted by an accumulated deficit of -$246.9M, leaving the firm with minimal operational runway.
Investors should remain cautious as the current cash position of $2.6M appears insufficient to support the capital-intensive nature of biotechnology development without immediate external intervention.

Verdict Logic

the company's critical liquidity position, characterized by a cash balance of only $2.6M against a history of significant quarterly burn, suggests an imminent risk of insolvency that outweighs potential pipeline upside.

HEPA Growth Metrics

Hepion Pharmaceuticals, Inc. (HEPA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM81.86%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM99.69%

Return on Capital

10 Years-195.89%

5 Years-253.69%

3 Years-387.75%

Last Year-671.34%

Peers Comparison

Key metrics vs top competitors for Hepion Pharmaceuticals, Inc. (HEPA)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
HEPAHepion Pharmaceuticals, Inc.Current	$0.06	$698.62K	-0.07	—	—	-2058.63%	—
MDGLMadrigal Pharmaceuticals, Inc.	$514.39	$11.86B	-40.03	432.05%	-27.32%	-50.15%	—
AKROAkero Therapeutics, Inc.	$54.65	$4.5B	-14.57	—	—	-30.58%	—
HALOHalozyme Therapeutics, Inc.	$77.01	$9.13B	30.08	37.55%	23.13%	126.27%	—
TERNTerns Pharmaceuticals, Inc.	$52.95	$4.77B	-51.41	—	—	-20.02%	—
ELVNEnliven Therapeutics, Inc.	$48.76	$2.97B	-26.64	—	—	-21.04%	—